title: Permanent, lowered HLA class I expression using lentivirus vectors with shRNA constructs: Averting cytotoxicity by alloreactive T lymphocytes.
abstract: Transplantation of many tissues requires histocompatibility matching of human leukocyte antigens (HLA) to prevent graft rejection, to reduce the level of immunosuppression needed to maintain graft survival, and to minimize the risk of graft-versus-host disease, particularly in the case of bone marrow transplantation. However, recent advances in fields of gene delivery and genetic regulation technologies have opened the possibility of engineering grafts that display reduced levels of HLA expression. Suppression of HLA expression could help to overcome the limitations imposed by extensive HLA polymorphisms that restrict the availability of suitable donors, necessitate the maintenance of large donor registries, and complicate the logistics of procuring and delivering matched tissues and organs to the recipient. Accordingly, we investigated whether knockdown of HLA by RNA interference (RNAi), a ubiquitous regulatory system that can efficiently and selectively inhibit the expression of specific gene products, would enable allogeneic cells to evade immune recognition. For efficient and stable delivery of short hairpin-type RNAi constructs (shRNA), we employed lentivirus-based gene transfer vectors, which provide a delivery system that can achieve integration into genomic DNA, thereby permanently modifying transduced graft cells. Our results show that lentivirus-mediated delivery of shRNA targeting pan-Class I and allele-specific HLA can achieve efficient and dose-dependent reduction in surface expression of HLA in human cells, associated with enhanced resistance to alloreactive T lymphocyte-mediated cytotoxicity, while avoiding MHC-non-restricted killing. We hypothesize that RNAi-induced silencing of HLA expression has the potential to create histocompatibility-enhanced, and, eventually, perhaps "universally" compatible cellular grafts.
authors.affiliation: Department of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA.
authors.forename: K
authors.initials: K
authors.lastname: Haga
authors.forename: N A
authors.initials: NA
authors.lastname: Lemp
authors.forename: C R
authors.initials: CR
authors.lastname: Logg
authors.forename: J
authors.initials: J
authors.lastname: Nagashima
authors.forename: E
authors.initials: E
authors.lastname: Faure-Kumar
authors.forename: G G
authors.initials: GG
authors.lastname: Gomez
authors.forename: C A
authors.initials: CA
authors.lastname: Kruse
authors.forename: R
authors.initials: R
authors.lastname: Mendez
authors.forename: R
authors.initials: R
authors.lastname: Stripecke
authors.forename: N
authors.initials: N
authors.lastname: Kasahara
authors.forename: N A
authors.initials: NA
authors.lastname: Kasahara
authors.forename: J C
authors.initials: JC
authors.lastname: Cicciarelli
mesh_terms: D001483:Base Sequence; D002460:Cell Line; D003602:Cytotoxicity, Immunologic; D017931:DNA Primers; D020868:Gene Silencing; D018014:Gene Transfer Techniques; D005822:Genetic Vectors; D006678:HIV / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000276:immunology; D007668:Kidney; D016086:Lentivirus; D034622:RNA Interference; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D017931:DNA Primers; D015395:Histocompatibility Antigens Class I; D007371:Interferon-gamma